Mason Marks, JAMA Network…
Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus Statement
Amy L. McGuire, I. Glenn Cohen, Dominic Sisti, Mason Marks, et. al., JAMA Network As government agencies around the globe contemplate approval of the first psychedelic medicines, many questions remain about their ethical integration into mainstream medical practice. From June 9 to 12, 2023, 27 individuals representing the perspectives of clinicians, researchers, Indigenous groups, industry,…
Branching Regulatory Paths and Dead Ends in Psychedelics
I. Glenn Cohen, The Regulatory Review The convergence of current psychedelics regulatory pathways may bring benefits and new challenges….
Essentials of Informed Consent to Psychedelic Medicine
Mason Marks, Rebecca W. Brendel, Carmel Shachar, I. Glenn Cohen, JAMA Psychiatry Analysis of the challenges of designing and implementing psychedelic informed consent practices revealed 7 essential components, including the possibility of short- and long-term perceptual disturbances, potential personality changes and altered metaphysical beliefs, the limited role of reassuring physical touch, the potential for patient abuse or coercion, the role and risks…